Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer.
Viruses have been engineered for cancer therapy in a variety of ways. Approaches include non-replicating gene therapy vectors, cancer vaccines and oncolytic viruses, but the clinical efficacy of these approaches has been limited by multiple factors. However, a new therapeutic class of oncolytic poxviruses has recently been developed that combines targeted and armed approaches for treating cancer. Initial preclinical and clinical results show that products from this therapeutic class can systemically target cancers in a highly selective and potent fashion using a multi-pronged mechanism of action.
Kirn
David H
DH
Jennerex Biotherapeutics Inc., San Francisco, California 94105, USA . dkirn@jennerex.com
Thorne
Steve H
SH
D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use; D005544:Forecasting; D015967:Gene Expression Regulation, Viral; D054884:Host-Pathogen Interactions; D006801:Humans; D007111:Immunity, Cellular; D007249:Inflammation; D051379:Mice; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000098:blood supply / Q000628:therapy*; D050130:Oncolytic Virotherapy; D050504:Oncolytic Viruses / Q000235:genetics / Q000276:immunology / Q000502:physiology*; D011212:Poxviridae / Q000235:genetics / Q000276:immunology / Q000502:physiology*; D014616:Vaccinia virus / Q000235:genetics / Q000276:immunology / Q000502:physiology; D014779:Virus Replication
D019496:Cancer Vaccines